Methodological standards for using the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in cancer clinical trials

Clin Trials. 2022 Jun;19(3):274-276. doi: 10.1177/17407745221093922. Epub 2022 May 15.

Authors

Ethan Basch¹, Gita Thanarajasingam², Amylou C Dueck³

Affiliations

¹ Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
² Division of Hematology, Mayo Clinic, Rochester, MN, USA.
³ Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ, USA.

PMID: 35575014
DOI: 10.1177/17407745221093922

No abstract available

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Antineoplastic Agents* / adverse effects
Humans
Neoplasms* / drug therapy
Patient Reported Outcome Measures

Substances

Antineoplastic Agents

Grants and funding

U01 CA233046/CA/NCI NIH HHS/United States